

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional application
under 37 CFR 1.53(b))

APPLICATION ELEMENTS
See MPEP chapter 600 concerning utility patent
application contents.

1. ☒ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification Total Pages
(preferred arrangement set forth below)
 - Descriptive Title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Sequence Listing or a Table Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 USC 113) Total Sheets
4. ☒ Oath or Declaration/
Power of Attorney Total Sheets
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 16 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 CFR 1.63(d)(2) and 1.33(b).
5. ☐ Application Data Sheet (See 37 CFR 1.76)

CERTIFICATE UNDER 37 C.F.R. 1.10

Docket No.

IVD 938-2

Express Mail Label No.: EL676469475US

Date of Deposit: March 26, 2004

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to: Mail Stop Patent Applications, Commissioner for Patents, P.O. Box 1450, Arlington, VA 22313-1450

Geraldine A. Shei
Signature

ADDRESS TO: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

6. ☐ CD-Rom or CD-R, Large Table or Computer Program
(Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☐ Computer Readable Form (CFR)
 - b. ☐ Paper copy (identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Request and Certification under 35 U.S.C. 122(b)(2)(B)(i)
15. ☒ Other: Citation of References

16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application no: 09/125,168

Prior Application Information:

Examiner: Joseph F. Murphy

Group Art Unit: 1646

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☒ Customer Number: 27546 or ☒ Correspondence address below

Paul E. Dupont
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Telephone No.: (610) 889-6338
Facsimile No.: (610) 889-8799

Respectfully submitted

Paul E. Dupont
Reg. No. 27,438

17610 U.S. PTO
10/810109

032604

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Divisional Under 37 C.F.R. 1.53(b)
Application of: Bach et al.

Prior Application Serial No.: 09/125,168

Prior Filing Date: 18 August 1998

Prior Group Art Unit: 1646

Examiner: Joseph F. Murphy

For: USE OF IL-7 FOR TREATING AUTOIMMUNE
DISEASES AND INSULIN DEPENDENT DIABETES
MELLITUS IN PARTICULAR

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label Number: EL676469475US

Date of Deposit: March 26, 2004

I hereby certify that this paper is being deposited with the
United States Postal Service "Express Mail Post Office to
Addressee" Service on the date indicated above and is
addressed to: Mail Stop Patent Application, Commissioner
for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Signature *Geraldine A. Baker*

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Washington, D.C. 20231

FEE TRANSMITTAL FORM

The filing fee for the above-identified has been calculated as shown below:

	Number Filed	<u>Claims as Filed</u>		Number Extra	Rate	Basic Fee \$770.00
Total Claims	16	-20 =	0	X	\$ 18.00 =	0.00
Independent Claims	3	- 3 =	0	X	\$ 86.00 =	0.00
Multiple dependent claims(s), if any					\$290.00 =	
Total Filing Fee:						\$770.00

☒ Please charge the following fees to Deposit Account No. 19-0091.

☒ Filing Fee of \$ 770.00
☐ Assignment recordal fee of \$

Please charge any additional fees under 37 CFR 1.16 which may be required, or credit any
overpayment, to Deposit Account No. 19-0091. A duplicate copy of this sheet is enclosed.

☒ This application is being filed by "Express Mail" as of the date of this letter pursuant to
37 CFR 1.10(b).

Date: 3/26/04

Paul E. Dupont
Paul E. Dupont
Reg. No. 27,438

Address:
Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Tele: (610) 889-6338
Fax: (610) 889-8799

Application of: Bach et al

Docket No.: IVD 938-2

Divisional of U.S. Application Serial No. 09/125,168

FOR: USE OF IL-7 FOR TREATING AUTOIMMUNE DISEASES AND
INSULIN DEPENDENT DIABETES MELLITUS IN PARTICULAR

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.: EL676469475US

Date of Deposit: March 26, 2004

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to:

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Signature